US Stock MarketDetailed Quotes

TNXP Tonix Pharmaceuticals

Watchlist

0.1897
+0.0014+0.74%

Close Nov 29 13:00 ET

0.1899
+0.0002+0.11%

Post 16:59 ET

35.45MMarket Cap-2P/E (TTM)

Tonix Pharmaceuticals Stock Forum

Angelos

Nov 27 11:01

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Angelos

Nov 27 10:57

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

Nov 27 10:23

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

Nov 27 10:15

$Tonix Pharmaceuticals (TNXP.US)$ https://youtu.be/v_VIj3lMETU?si=mKwShpRtJb54IFS2

我要向钱看

Nov 27 10:05

CONTINUE FROM PREVIOUS UPDATE

$Tonix Pharmaceuticals (TNXP.US)$ Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ:TNXP), joined Steve Darling from Proactive to unveil promising results at the ACR Convergence 2024 Annual Meeting from the company’s Phase 3 RESILIENT trial of its proprietary sublingual bedtime medication for fibromyalgia. The trial met its primary endpoint, achieving a statistically significant reduction in daily pain compared to a placebo.
Additionally, the treatment demonstr...